Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yang, Bo ^a   Yu, Rui li ^a   Chi, Xiao hua ^b   Lu, Xue chun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Second Artillery General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LOW DRUG DOSE; META ANALYSIS; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

DISEASE-FREE SURVIVAL; HUMANS; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84877787623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064354     Document Type: Article

References (31)

1. Slovak ML, (2011) Multiple myeloma: current perspectives. Clin Lab Med 31: 699-724.
2. Pingali SR, Haddad RY, Saad A, (2012) Current concepts of clinical management of multiple myeloma. Dis Mon 58: 195-207.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008: Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France:International Agency for Research on Cancer. Available from http://globocan.iarc.fr. Accessed 20 March 2013.
4. Palumbo A, Rajkumar SV, (2009) Treatment of newly diagnosed myeloma. Leukemia 23: 449-456.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883.
6. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, et al. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99: 3163-3168.
7. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, et al. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24: 929-936.
8. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, et al. (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117: 4696-4700.
9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520.
10. Scott LJ, Lyseng-Williamson KA, (2011) Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 71: 625-649.
11. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, et al. (2002) Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130: 75-84.
12. Dimopoulos MA, Eleutherakis-Papaiakovou V, (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117: 508-515.
13. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF, (2008) New drugs in multiple myeloma: mechanisms of action and phaseI/II clinical findings. Lancet Oncol 9: 1157-1165.
14. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma Version 1. Available at http://www.nccn.org. Accessed 20 March 2013.
15. Cives M, Milano A, Dammacco F, Silvestris F, (2012) Lenalidomide in multiple myeloma: current experimental and clinical data. Eur J Haematol 88: 279-291.
16. Higgins JPT, Green S, Eds. (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. West Susex, England: John Wiley & Sons Ltd. and The Cochrane Collaboration. 190-202 p.
17. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102: 1115-1123.
18. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62: e1-e34.
20. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
21. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, et al. (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366: 1759-1769.
22. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, et al. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11: 29-37.
23. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF Sr, et al. (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116: 5838-5841.
24. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133-2142.
25. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, et al. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1782-1791.
26. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132.
27. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, et al. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1770-1781.
28. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, et al. (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115: 1343-1350.
29. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, et al. (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112: 4445-4451.
30. Gonzalez Rodriguez AP, (2011) Management of the adverse effects of lenalidomide in multiple myeloma. Adv Ther 28Suppl 1: 1-10.
31. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, et al. (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119: 933-939.